Search: WFRF:(Ustun Celalettin)
> (2018) >
Myeloablative vs re...
-
Chhabra, SaurabhMed Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA
(author)
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
- Article/chapterEnglish2018
Publisher, publication year, extent ...
-
2018-11-05
-
American Society of Hematology,2018
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-371540
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-371540URI
-
https://doi.org/10.1182/bloodadvances.2018024844DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:142588656URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease status at transplant was divided into the following categories: chronic phase 1, chronic phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and alternative donor transplants were excluded. The primary outcome was overall survival (OS) after allo-HCT. MAC (n = 1204) and RIC allo-HCT recipients (n = 191) from 2007 to 2014 were included. Patient, disease, and transplantation characteristics were similar, with a few exceptions. Multivariable analysis showed no significant difference in OS between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P = .001). The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with RIC than with MAC (HR, 0.77; P = .02). RIC provides similar survival and lower cGVHD compared with MAC and therefore may be a reasonable alternative to MAC for CML patients in the TKI era.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Ahn, Kwang WooMed Coll Wisconsin, Inst Hlth & Soc, Dept Biostat, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
(author)
-
Hu, Zhen-HuanMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
(author)
-
Jain, SandeepMed Univ South Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA
(author)
-
Assal, AmerColumbia Univ, Med Ctr, New York, NY USA
(author)
-
Cerny, JanUMass Mem Med Ctr, Worcester, MA USA
(author)
-
Copelan, Edward A.Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
(author)
-
Daly, AndrewTom Baker Canc Clin, Calgary, AB, Canada
(author)
-
DeFilipp, ZachariahMassachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA 02114 USA
(author)
-
Gadalla, Shahinaz M.NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA
(author)
-
Gale, Robert PeterImperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England
(author)
-
Ganguly, SiddharthaUniv Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA
(author)
-
Hamilton, Betty K.Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
(author)
-
Hildebrandt, Gerhard CarlUniv Kentucky, Markey Canc Ctr, Lexington, KY USA
(author)
-
Hsu, Jack W.Shands HealthCare, Dept Med, Div Hematol & Oncol, Gainesville, FL USA;Univ Florida, Gainesville, FL USA
(author)
-
Inamoto, YoshihiroNatl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan
(author)
-
Kanate, Abraham S.West Virginia Univ, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA
(author)
-
Khoury, H. JeanEmory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
(author)
-
Lazarus, Hillard M.Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Seidman Canc Ctr, Cleveland, OH 44106 USA
(author)
-
Litzow, Mark R.Mayo Clin Rochester, Div Hematol & Transplant Ctr, Rochester, MN USA
(author)
-
Nathan, SunitaRush Univ, Med Ctr, Chicago, IL 60612 USA
(author)
-
Olsson, RichardKarolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden(Swepub:uu)riols677
(author)
-
Pawarode, AttapholUniv Michigan, Dept Internal Med, Div Hematol Oncol, Med Sch,Blood & Marrow Transplantat Program, Ann Arbor, MI 48109 USA
(author)
-
Ringden, OlleKarolinska Institutet
(author)
-
Rowe, Jacob M.Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel
(author)
-
Saad, AymanUniv Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA
(author)
-
Savani, Bipin N.Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA
(author)
-
Schouten, Harry C.Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands
(author)
-
Seo, SachikoNatl Canc Res Ctr East, Dept Hematol & Oncol, Chiba, Japan
(author)
-
Shah, Nirav N.Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA
(author)
-
Solh, MelhemNorthside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA
(author)
-
Stuart, Robert K.Med Univ South Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA
(author)
-
Ustun, CelalettinUniv Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
(author)
-
Woolfrey, Ann E.Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
(author)
-
Yared, Jean A.Univ Maryland, Greenebaum Canc Ctr, Div Hematol Oncol, Blood & Marrow Transplantat Program,Dept Med, Baltimore, MD 21201 USA
(author)
-
Alyea, Edwin P.Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA
(author)
-
Kalaycio, Matt E.Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
(author)
-
Popat, UdayUniv Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
(author)
-
Sobecks, Ronald M.Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
(author)
-
Saber, WaelMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
(author)
-
Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USAMed Coll Wisconsin, Inst Hlth & Soc, Dept Biostat, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
(creator_code:org_t)
Related titles
-
In:Blood Advances: American Society of Hematology2:21, s. 2922-29362473-95292473-9537
Internet link
Find in a library
To the university's database
- By the author/editor
-
Chhabra, Saurabh
-
Ahn, Kwang Woo
-
Hu, Zhen-Huan
-
Jain, Sandeep
-
Assal, Amer
-
Cerny, Jan
-
show more...
-
Copelan, Edward ...
-
Daly, Andrew
-
DeFilipp, Zachar ...
-
Gadalla, Shahina ...
-
Gale, Robert Pet ...
-
Ganguly, Siddhar ...
-
Hamilton, Betty ...
-
Hildebrandt, Ger ...
-
Hsu, Jack W.
-
Inamoto, Yoshihi ...
-
Kanate, Abraham ...
-
Khoury, H. Jean
-
Lazarus, Hillard ...
-
Litzow, Mark R.
-
Nathan, Sunita
-
Olsson, Richard
-
Pawarode, Attaph ...
-
Ringden, Olle
-
Rowe, Jacob M.
-
Saad, Ayman
-
Savani, Bipin N.
-
Schouten, Harry ...
-
Seo, Sachiko
-
Shah, Nirav N.
-
Solh, Melhem
-
Stuart, Robert K ...
-
Ustun, Celaletti ...
-
Woolfrey, Ann E.
-
Yared, Jean A.
-
Alyea, Edwin P.
-
Kalaycio, Matt E ...
-
Popat, Uday
-
Sobecks, Ronald ...
-
Saber, Wael
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
Blood Advances
- By the university
-
Uppsala University
-
Karolinska Institutet